Salbutamol: A Safety Meta-Analysis Overview Salbutamol, a widely used bronchospasm reliever, has been insufficiently scrutinized for potential risks. In a meta-analysis of 58 randomized controlled trials with 12,961 participants, the study unearthed a 34% incidence of total adverse events (AEs). Notably, severe AEs stood at 2%, and treatment discontinuation was 3%. Subgroup
Tag: COPD
COPD Risk With Diabetes And Pre-Diabetes
COPD Risk With Diabetes And Pre-Diabetes A new trail-blazing study links diabetes, pre-diabetic states, and an extended duration of diabetes to an increased risk of chronic obstructive pulmonary disease development. This article will explore this ground-breaking research and its findings. Background of the Study Diabetes and chronic obstructive pulmonary diseases (COPD) are among
